Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Gastroenterology
Published in: BMC Gastroenterology 1/2009

Open Access 01-12-2009 | Research article

Investigation of innate immunity genes CARD4, CARD8 and CARD15 as germline susceptibility factors for colorectal cancer

Authors: Nikolaus Möckelmann, Witigo von Schönfels, Stephan Buch, Oliver von Kampen, Bence Sipos, Jan Hendrik Egberts, Philip Rosenstiel, Andre Franke, Mario Brosch, Sebastian Hinz, Christian Röder, Holger Kalthoff, Ulrich R Fölsch, Michael Krawczak, Stefan Schreiber, Clemens Dieter Bröring, Jürgen Tepel, Clemens Schafmayer, Jochen Hampe

Published in: BMC Gastroenterology | Issue 1/2009

Login to get access

Abstract

Background

Variation in genes involved in the innate immune response may play a role in the predisposition to colorectal cancer (CRC). Several polymorphisms of the CARD15 gene (caspase activating recruitment domain, member 15) have been reported to be associated with an increased susceptibility to Crohn disease. Since the CARD15 gene product and other CARD proteins function in innate immunity, we investigated the impact of germline variation at the CARD4, CARD8 and CARD15 loci on the risk for sporadic CRC, using a large patient sample from Northern Germany.

Methods

A total of 1044 patients who had been operated with sporadic colorectal carcinoma (median age at diagnosis: 59 years) were recruited and compared to 724 sex-matched, population-based control individuals (median age: 68 years). Genetic investigation was carried out following both a coding SNP and haplotype tagging approach. Subgroup analyses for N = 143 patients with early manifestation of CRC (≤50 age at diagnosis) were performed for all CARD loci and subgroup analyses for diverse age strata were carried out for CARD15 mutations R702W, G908R and L1007fs. In addition, all SNPs were tested for association with disease presentation and family history of CRC.

Results

No significant differences were observed between the patient and control allelic or haplotypic spectra of the three genes under study for the total cohort (N = 1044 patients). None of the analysed SNPs was significantly associated with either tumour location or yielded significant association in the familial or non-familial CRC patient subgroups. However, in a patient subgroup (≤45 age at diagnosis) with early disease manifestation the mutant allele of CARD15 R702W was found to be significantly associated with disease susceptibility (9.7% in cases vs 4.6% in controls; Pallelic = 0.008, Pgenotypic = 0.0008, ORallelic = 2.22 (1.21-4.05) ORressessive = 21.9 (1.96-245.4).

Conclusion

Variation in the innate immunity genes CARD4, CARD8 and CARD15 is unlikely to play a major role in the susceptibility to CRC in the German population. But, we report a significant disease contribution of CARD15 for CRC patients with very early disease manifestation, mainly driven by variant R702W.
Appendix
Available only for authorised users
Literature
1.
Hemminki K, Chen B: Familial risk for colorectal cancers are mainly due to heritable causes. Cancer Epidemiol Biomarkers Prev. 2004, 13 (7): 1253-1256.PubMed
2.
Andrieu N, Launoy G, Guillois R, Ory-Paoletti C, Gignoux M: Familial relative risk of colorectal cancer: a population-based study. Eur J Cancer. 2003, 39 (13): 1904-1911. 10.1016/S0959-8049(03)00420-9.CrossRefPubMed
3.
Johns LE, Kee F, Collins BJ, Patterson CC, Houlston RS: Colorectal cancer mortality in first-degree relatives of early-onset colorectal cancer cases. Dis Colon Rectum. 2002, 45 (5): 681-686. 10.1007/s10350-004-6267-0.CrossRefPubMed
4.
Balkwill F, Mantovani A: Inflammation and cancer: back to Virchow?. Lancet. 2001, 357 (9255): 539-545. 10.1016/S0140-6736(00)04046-0.CrossRefPubMed
5.
Munkholm P: Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther. 2003, 18 (Suppl 2): 1-5. 10.1046/j.1365-2036.18.s2.2.x.CrossRefPubMed
6.
Rhodes JM, Campbell BJ: Inflammation and colorectal cancer: IBD-associated and sporadic cancer compared. Trends Mol Med. 2002, 8 (1): 10-16. 10.1016/S1471-4914(01)02194-3.CrossRefPubMed
7.
Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J, Almer S, Tysk C, O'Morain CA, Gassull M, et al: Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature. 2001, 411 (6837): 599-603. 10.1038/35079107.CrossRefPubMed
8.
Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, Britton H, Moran T, Karaliuskas R, Duerr RH, et al: A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature. 2001, 411 (6837): 603-606. 10.1038/35079114.CrossRefPubMed
9.
Hampe J, Cuthbert A, Croucher PJ, Mirza MM, Mascheretti S, Fisher S, Frenzel H, King K, Hasselmeyer A, MacPherson AJ, et al: Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet. 2001, 357 (9272): 1925-1928. 10.1016/S0140-6736(00)05063-7.CrossRefPubMed
10.
Cuthbert AP, Fisher SA, Mirza MM, King K, Hampe J, Croucher PJ, Mascheretti S, Sanderson J, Forbes A, Mansfield J, et al: The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease. Gastroenterology. 2002, 122 (4): 867-874. 10.1053/gast.2002.32415.CrossRefPubMed
11.
Vermeire S, Wild G, Kocher K, Cousineau J, Dufresne L, Bitton A, Langelier D, Pare P, Lapointe G, Cohen A, et al: CARD15 genetic variation in a Quebec population: prevalence, genotype-phenotype relationship, and haplotype structure. Am J Hum Genet. 2002, 71 (1): 74-83. 10.1086/341124.CrossRefPubMedPubMedCentral
12.
Inohara N, Nunez G: The NOD: a signaling module that regulates apoptosis and host defense against pathogens. Oncogene. 2001, 20 (44): 6473-6481. 10.1038/sj.onc.1204787.CrossRefPubMed
13.
McGovern DP, Hysi P, Ahmad T, van Heel DA, Moffatt MF, Carey A, Cookson WO, Jewell DP: Association between a complex insertion/deletion polymorphism in NOD1 (CARD4) and susceptibility to inflammatory bowel disease. Hum Mol Genet. 2005, 14 (10): 1245-1250. 10.1093/hmg/ddi135.CrossRefPubMed
14.
McGovern DP, Butler H, Ahmad T, Paolucci M, van Heel DA, Negoro K, Hysi P, Ragoussis J, Travis SP, Cardon LR, et al: TUCAN (CARD8) Genetic Variants and Inflammatory Bowel Disease. Gastroenterology. 2006, 131 (4): 1190-1196. 10.1053/j.gastro.2006.08.008.CrossRefPubMed
15.
Kurzawski G, Suchy J, Kladny J, Grabowska E, Mierzejewski M, Jakubowska A, Debniak T, Cybulski C, Kowalska E, Szych Z: The NOD2 3020insC mutation and the risk of colorectal cancer. Cancer Res. 2004, 64 (5): 1604-1606. 10.1158/0008-5472.CAN-03-3791.CrossRefPubMed
16.
Papaconstantinou I, Theodoropoulos G, Gazouli M, Panoussopoulos D, Mantzaris GJ, Felekouras E, Bramis J: Association between mutations in the CARD15/NOD2 gene and colorectal cancer in a Greek population. Int J Cancer. 2005, 114 (3): 433-435. 10.1002/ijc.20747.CrossRefPubMed
17.
Roberts RL, Gearry RB, Allington MD, Morrin HR, Robinson BA, Frizelle FA: Caspase recruitment domain-containing protein 15 mutations in patients with colorectal cancer. Cancer Res. 2006, 66 (5): 2532-2535. 10.1158/0008-5472.CAN-05-4165.CrossRefPubMed
18.
Alhopuro P, Ahvenainen T, Mecklin JP, Juhola M, Jarvinen HJ, Karhu A, Aaltonen LA: NOD2 3020insC alone is not sufficient for colorectal cancer predisposition. Cancer Res. 2004, 64 (20): 7245-7247. 10.1158/0008-5472.CAN-04-2364.CrossRefPubMed
19.
Tuupanen S, Alhopuro P, Mecklin JP, Jarvinen H, Aaltonen LA: No evidence for association of NOD2 R702W and G908R with colorectal cancer. Int J Cancer. 2007, 121 (1): 76-79. 10.1002/ijc.22651.CrossRefPubMed
20.
Lakatos PL, Hitre E, Szalay F, Zinober K, Fuszek P, Lakatos L, Fischer S, Osztovits J, Gemela O, Veres G: Common NOD2/CARD15 variants are not associated with susceptibility or the clinicopathologic characteristics of sporadic colorectal cancer in Hungarian patients. BMC Cancer. 2007, 7: 54-10.1186/1471-2407-7-54.CrossRefPubMedPubMedCentral
21.
Krawczak M, Nikolaus S, von Eberstein H, El Mokhtari NE, Schreiber S: PopGen: Population-based recruitment of patients and controls for the analysis of complex genotype-phenotype relationships. Community Genet. 2006, 9 (1): 55-61. 10.1159/000090694.PubMed
22.
Rodriguez-Bigas MA, Boland CR, Hamilton SR, Henson DE, Jass JR, Khan PM, Lynch H, Perucho M, Smyrk T, Sobin L, et al: A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines. Journal of the National Cancer Institute. 1997, 89 (23): 1758-1762. 10.1093/jnci/89.23.1758.CrossRefPubMed
23.
Hampe J, Wollstein A, Lu T, Frevel HJ, Will M, Manaster C, Schreiber S: An integrated system for high throughput TaqMan based SNP genotyping. Bioinformatics (Oxford, England). 2001, 17 (7): 654-655. 10.1093/bioinformatics/17.7.654.CrossRef
24.
Hampe J, Grebe J, Nikolaus S, Solberg C, Croucher PJ, Mascheretti S, Jahnsen J, Moum B, Klump B, Krawczak M, et al: Association of NOD2 (CARD 15) genotype with clinical course of Crohn's disease: a cohort study. Lancet. 2002, 359 (9318): 1661-1665. 10.1016/S0140-6736(02)08590-2.CrossRefPubMed
25.
Altshuler D, Brooks LD, Chakravarti A, Collins FS, Daly MJ, Donnelly P: A haplotype map of the human genome. Nature. 2005, 437 (7063): 1299-1320. 10.1038/nature04226.CrossRef
26.
Dudbridge F: Pedigree disequilibrium tests for multilocus haplotypes. Genetic epidemiology. 2003, 25 (2): 115-121. 10.1002/gepi.10252.CrossRefPubMed
27.
Dupont WD, Plummer WD: PS power and sample size program available for free on the Internet. Controlled Clin Trials. 1997, 18: 274-10.1016/S0197-2456(97)00074-3.CrossRef
28.
de Bakker PI, Yelensky R, Pe'er I, Gabriel SB, Daly MJ, Altshuler D: Efficiency and power in genetic association studies. Nature genetics. 2005, 37 (11): 1217-1223. 10.1038/ng1669.CrossRefPubMed
29.
Barrett JC, Fry B, Maller J, Daly MJ: Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics (Oxford, England). 2005, 21 (2): 263-265. 10.1093/bioinformatics/bth457.CrossRef
30.
Franke A, Ruether A, Wedemeyer N, Karlsen TH, Nebel A, Schreiber S: No association between the functional CARD4 insertion/deletion polymorphism and inflammatory bowel diseases in the German population. Gut. 2006, 55 (11): 1679-1680. 10.1136/gut.2006.104646.CrossRefPubMedPubMedCentral
31.
Molnar T, Hofner P, Nagy F, Lakatos PL, et al: NOD1 gene E266K polymorphism is associated with disease susceptibility but not with disease phenotype or NOD2/CARD15 in Hungarian patients with Crohn's disease. Dig Liver Dis. 2007, 39: 1064-1070. 10.1016/j.dld.2007.09.003.CrossRefPubMed
32.
Croucher PJ, Mascheretti S, Hampe J, Huse K, Frenzel H, Stoll M, Lu T, Nikolaus S, Yang SK, Krawczak M, et al: Haplotype structure and association to Crohn's disease of CARD15 mutations in two ethnically divergent populations. Eur J Hum Genet. 2003, 11 (1): 6-16. 10.1038/sj.ejhg.5200897.CrossRefPubMed
33.
34.
Shacter E, Weitzman SA: Chronic inflammation and cancer. Oncology (Williston Park). 2002, 16 (2): 217-226. discussion 230-212.
35.
36.
Ke X, Durrant C, Morris AP, Hunt S, Bentley DR, Deloukas P, Cardon LR: Efficiency and consistency of haplotype tagging of dense SNP maps in multiple samples. Human molecular genetics. 2004, 13 (21): 2557-2565. 10.1093/hmg/ddh294.CrossRefPubMed
37.
Hirschhorn JN, Daly MJ: Genome-wide association studies for common diseases and complex traits. Nat Rev Genet. 2005, 6 (2): 95-108. 10.1038/nrg1521.CrossRefPubMed
38.
Helms C, Cao L, Krueger JG, Wijsman EM, Chamian F, Gordon D, Heffernan M, Daw JA, Robarge J, Ott J, et al: A putative RUNX1 binding site variant between SLC9A3R1 and NAT9 is associated with susceptibility to psoriasis. Nature genetics. 2003, 35 (4): 349-356. 10.1038/ng1268.CrossRefPubMed
39.
Tokuhiro S, Yamada R, Chang X, Suzuki A, Kochi Y, Sawada T, Suzuki M, Nagasaki M, Ohtsuki M, Ono M, et al: An intronic SNP in a RUNX1 binding site of SLC22A4, encoding an organic cation transporter, is associated with rheumatoid arthritis. Nature genetics. 2003, 35 (4): 341-348. 10.1038/ng1267.CrossRefPubMed
40.
Robert-Koch-Institut: Krebs in Deutschland 2003-2004. Häufigkeiten und Trends. überarbeitete Auflage. Berlin: Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. 2008, 6:
41.
Claus EB, Risch NJ, Thompson WD: Age at onset as an indicator of familial risk of breast cancer. American journal of epidemiology. 1990, 131 (6): 961-972. 10.1002/mds.20663.PubMed
42.
Pankratz N, Byder L, Halter C, Rudolph A, Shults CW, Conneally PM, Foroud T, Nichols WC: Presence of an APOE4 allele results in significantly earlier onset of Parkinson's disease and a higher risk with dementia. Mov Disord. 2006, 21 (1): 45-49. 10.1002/gepi.20043.CrossRefPubMed
43.
Pankratz VS, de Andrade M, Therneau TM: Random-effects Cox proportional hazards model: general variance components methods for time-to-event data. Genetic epidemiology. 2005, 28 (2): 97-109. 10.1093/hmg/ddm169.CrossRefPubMed
44.
van Limbergen J, Nimmo ER, Russell RK, et al: Investigation of NOD1/CARD4 variation in inflammatory bowel disease using a haplotype-tagging strategy. Hum Mol Genet. 2007, 16 (18): 2175-2186. 10.1053/gast.2003.50019.CrossRefPubMed
45.
Bonen DK, Ogura Y, Nicolae DL, et al: Crohn's Disease-Associated NOD2 Variants Share a Signaling Defect in Response to Lipopolysaccharide and Peptidoglycan. Gastroenterology. 2003, 124: 140-146. 10.1016/j.micinf.2007.01.015.CrossRefPubMed
46.
Rosenstiel P, Till A, Schreiber S: NOD-like receptors and human diseases. Microbes and Infection. 2007, 648-657. 10.1038/ng2085. 9
47.
Tomlinson I, Webb E, Carvajal-Carmona L, Broderick P, Kemp Z, Spain S, Penegar S, Chandler I, Gorman M, Wood W: A genome-wide association scan of tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24.21. Nat Genet. 2007, 39 (8): 984-988. 10.1038/ng2089.CrossRefPubMed
48.
Zanke BW, Greenwood CM, Rangrej J, Kustra R, Tenesa A, Farrington SM, Prendergast J, Olschwang S, Chiang T, Crowdy E: Genome-wide association scan identifies a colorectal cancer susceptibility locus on chromosome 8q24. Nat Genet. 2007, 39 (8): 989-994. 10.1038/ng.111.CrossRefPubMed
49.
Tomlinson IP, Webb E, Carvajal-Carmona L, Broderick P, Howarth K, Pittman AM, Spain S, Lubbe S, Walther A, Sullivan K: A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3. Nat Genet. 2008, 40 (5): 623-630. 10.1038/ng.133.CrossRefPubMed
50.
Tenesa A, Farrington SM, Prendergast JG, Porteous ME, Walker M, Haq N, Barnetson RA, Theodoratou E, Cetnarskyj R, Cartwright N: Genome-wide association scan identifies a colorectal cancer susceptibility locus on 11q23 and replicates risk loci at 8q24 and 18q21. Nat Genet. 2008, 40 (5): 631-637. 10.1038/ng.2007.18.CrossRefPubMedPubMedCentral
51.
Broderick P, Carvajal-Carmona L, Pittman AM, Webb E, Howarth K, Rowan A, Lubbe S, Spain S, Sullivan K, Fielding S: A genome-wide association study shows that common alleles of SMAD7 influence colorectal cancer risk. Nat Genet. 2007, 39 (11): 1315-1317. 10.1038/ng.262.CrossRefPubMed
52.
Houlston RS, Webb E, Broderick P, Pittman AM, Di Bernardo MC, Lubbe S, Chandler I, Vijayakrishnan J, Sullivan K, Penegar S: Meta-analysis of genome-wide association data identifies four new susceptibility loci for colorectal cancer. Nat Genet. 2008, 40 (12): 1426-1435. 10.1038/ng.2007.41.CrossRefPubMed
53.
Jaeger E, Webb E, Howarth K, Carvajal-Carmona L, Rowan A, Broderick P, Walther A, Spain S, Pittman A, Kemp Z, et al: Common genetic variants at the CRAC1 (HMPS) locus on chromosome 15q13.3 influence colorectal cancer risk. Nat Genet. 2008, 40 (1): 26-28. 10.1002/ijc.23872.CrossRefPubMed
54.
Schafmayer C, Buch S, Volzke H, von Schonfels W, Egberts JH, Schniewind B, Brosch M, Ruether A, Franke A, Mathiak M, et al: Investigation of the colorectal cancer susceptibility region on chromosome 8q24.21 in a large German case-control sample. Int J Cancer. 2009, 124 (1): 75-80. 10.1038/sj.gene.6364111.CrossRefPubMed
55.
Arnott ID, Nimmo ER, Drummond HE, Fennell J, Smith BR, MacKinlay E, Morecroft J, Anderson N, Kelleher D, O'Sullivan M: NOD2/CARD15, TLR4 and CD14 mutations in Scottish and Irish Crohn's disease patients: evidence for genetic heterogeneity within Europe?. Genes Immun. 2004, 5 (5): 417-425. 10.1038/sj.gene.6364111.CrossRefPubMed
Metadata
Title
Investigation of innate immunity genes CARD4, CARD8 and CARD15 as germline susceptibility factors for colorectal cancer
Authors
Nikolaus Möckelmann
Witigo von Schönfels
Stephan Buch
Oliver von Kampen
Bence Sipos
Jan Hendrik Egberts
Philip Rosenstiel
Andre Franke
Mario Brosch
Sebastian Hinz
Christian Röder
Holger Kalthoff
Ulrich R Fölsch
Michael Krawczak
Stefan Schreiber
Clemens Dieter Bröring
Jürgen Tepel
Clemens Schafmayer
Jochen Hampe
Publication date
01-12-2009
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2009
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/1471-230X-9-79

Other articles of this Issue 1/2009

BMC Gastroenterology 1/2009 Go to the issue

Research article

Predictors of esophageal varices in patients with HBV-related cirrhosis: a retrospective study

Research article

Meta-analysis of percutaneous radiofrequency ablation versus ethanol injection in hepatocellular carcinoma

Research article

Decreasing incidence of peptic ulcer complications after the introduction of the proton pump inhibitors, a study of the Swedish population from 1974–2002

Research article

Mortality with upper gastrointestinal bleeding and perforation: effects of time and NSAID use

Research article

An association between colonic adenoma and abdominal obesity: a cross-sectional study

Research article

Serum procalcitonin and CRP levels in non-alcoholic fatty liver disease: a case control study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits